

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10713808	
	Filing Date		2003-11-14	
	First Named Inventor	Dave S.B. Hoon		
	Art Unit	1642		
	Examiner Name	Sean E. Aeder		
Attorney Docket Number		JWCI 0035 PUSP		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

1	ZEHENTNER ET AL., "Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA," Clinical Chemistry, 50: 2069-76, 2004	<input type="checkbox"/>
2	SCHULTZ ET AL., "A MAGE-A3 Peptide Presented by HLA-DP4 is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes," Cancer Research, 60: 6272-5, 2000	<input type="checkbox"/>
3	SCHUSTER, R. ET AL., "Quantitative Real-Time RT-PCR for Detection of Disseminated Tumor Cells in Peripheral Blood of Patients with Colorectal Cancer Using Different mRNA Markers," Int. J. Cancer, v. 108, n. 2, pp. 219-227, 1-10-2004	<input type="checkbox"/>
4	SOONG ET AL., "Quantitative Reverse Transcription-Polymerase Chain Reaction Detection of Cytokeratin 20 in Noncolorectal Lymph Nodes," Clinical Cancer Res., v. 7, 3423-3429, 2001	<input type="checkbox"/>
5	SORENSEN, B.S. ET AL., "Quantification of Melanoma Cell-specific MART-1 mRNA in Peripheral Blood by a Calibrated Competitive Reverse Transcription-PCR," Clinical Chemistry 46:12, 9-26-2000, pp. 1923-1928	<input type="checkbox"/>
6	STATHOPOULOU ET AL., "Real Time Quantification of CK-19 mRNA-Positive Cells in Peripheral Blood of Breast Cancer Patients Using the Lightcycler System," Clinical Cancer Research, 9: 5145-5151, 2003	<input type="checkbox"/>
7	TABACK ET AL., "Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease," Cancer Research, 61: 8845-8850, 2001	<input type="checkbox"/>
8	TAKEUCHI ET AL., "Expression of Differentiation Melanoma-Associated Antigen Genes is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas," Cancer Research, 63: 441-8, 2003	<input type="checkbox"/>
9	TAKEUCHI ET AL., "Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients," J. Clinical Oncology, 22: 2671-80, 2004	<input type="checkbox"/>
10	VOIT ET AL., "Molecular Staging in Stage II and III Melanoma Patients and its Effect on Long-Term Survival," J. Clinical Oncology, 23: 1218-1227, 2005	<input type="checkbox"/>
11	WASCHER ET AL., "Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated with a Melanoma Vaccine," J. Clinical Oncology, 21: 2558-63, 2003	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

12	WASCHER ET AL., "Stannicalcin-1: A Novel Molecular Blood and Bone Marrow Marker for Human Breast Cancer," Clinical Cancer Res., 9: 1427-35, 2003	<input type="checkbox"/>
13	BALCH ET AL., "Efficacy of an Elective Regional Lymph Node Dissection of 1 to 4 mm Thick Melanomas for Patients 60 Years of Age and Younger," Ann. Surg. 1996; 224:255-63	<input type="checkbox"/>
14	BALCH ET AL., "A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (stage I) Melanoma Treated in Alabama, USA and New South Wales, Australia, Ann. Surg. 196:677-684, 1982	<input type="checkbox"/>
15	CASCINELLI ET AL., "Immediate or Delayed Dissection of Regional Nodes in Patients with Melanoma of the Trunk: a Randomized Trial," WHO Melanoma Programme. Lancet, 1998; 351:796-6	<input type="checkbox"/>
16	CLEGG, R.M., "Fluorescence Energy Transfer,," Curr. Opin. Biotech, 6: 103-110, 1995	<input type="checkbox"/>
17	COCHRAN ET AL., "Occult Melanoma in Lymph Nodes Detected by Antiserum to S-100 Protein," Int. J. Cancer, 1984; 34:159-63	<input type="checkbox"/>
18	JEMAL ET AL., Cancer Statistics 2002, CA Cancer J. Clin., 52: 23-47, 2002	<input type="checkbox"/>
19	KAWAKAMI ET AL., "Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with In Vivo Tumor Rejection," Proc. Natl. Acad. Sci., USA, 91: 6458-6462, 1994	<input type="checkbox"/>
20	MORTON ET AL., "Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine," Ann. Surg. 1992; 216:463-82	<input type="checkbox"/>
21	RIGEL ET AL., "The Incidence of Malignant Melanoma in the United States: Issues as we Approach the 21st Century," J. Am. Acad. Dermatol., 34: 839-847, 1996	<input type="checkbox"/>
22	SHIVERS ET AL., "Molecular Staging of Malignant Melanoma: Correlation with Clinical Outcome," JAMA 1998, 280 1410-5	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

23	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma, J. Clin. Oncol., 16: 3635-3648, 2001	<input type="checkbox"/>
24	SPECHT, K. ET AL., "Quantitative Gene Expression Analysis in Microdissected Archival Tissue by Real-Time RT-PCR," J. Mol. Med. 78: B27, 2000 (Abstract)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.